Daily Biotech Movers — 2026-10-22: The Tails Were Set by Other People's Information

Thursday, October 22, 2026 was the second consecutive down session, and it was a narrower one than the first. Across the ~570 public biotech and life-sciences companies we track, all 570 carried a directional print — 246 finished higher against 306 lower, an advancer-to-decliner ratio of 0.80-to-1 — with eighteen names unchanged on the day. The median move was -0.31% and the mean -0.71%, on a standard deviation of 5.01%. The average advancer gained +2.88% while the average decliner lost -3.64%. 118 names cleared the anomaly filter and 104 moved at least 5%, with 27 of them printing at least twice their 30-day average volume.

The shape of the session is what matters, not its direction. Wednesday’s median was -0.42% on a standard deviation of 4.83%; Thursday’s was -0.31% on 5.01%. The centre of the distribution improved by eleven basis points while the tails widened: the spread between the best and worst print went from 63.5 points to 71.4 points — Estrella Immunopharma +32.15% at one end, Avalo Therapeutics -39.23% at the other. Breadth deteriorated slightly (249 advancers on Wednesday against 246 on Thursday) while the median decline got shallower, which is the signature of a market that is selling the cohort in an orderly way and repricing a handful of individual names violently.

The macro tape did the opposite of the cohort. The S&P 500 fell -1.17% while the health care sector proxy rose +1.33% — a 2.50-point outperformance, and the mirror image of Wednesday’s one-point lag. Inside health care, though, the split was unkind to biotechnology: the broad biotech proxy slipped -0.69% and the large-cap biotech proxy fell -0.95%, so the money that entered health care on Thursday entered the defensive, revenue-generating end of it and did not reach clinical-stage equities at all. On a day when the index lost more than a point, the sector that outperformed was the one with cash flows, not the one with catalysts.

And the leaderboard was, for the fifth time this month, mostly about capital and information rather than about medicine. Only one of the six largest movers — Korro Bio — was driven by a company press release issued that morning. The other five were moved by a rival’s Phase 3 readout (Avalo), a dataset that leaked onto social media before its scheduled release (Moderna), a compliance mechanic (Sunshine Biopharma), a week-old safety release still being re-rated (Estrella), and a regulatory clock that has not yet rung (Karyopharm). Not one of Thursday’s six extremes was a same-day clinical win or failure of the moving company’s own making. That distinction is the whole analysis.

The 6 Classes of Mover Signal

Every anomaly-flagged move is assigned to one of six classes, and the class is what separates information from mechanics. Class 1 — halt-release: a name resumes trading after a regulatory or news halt and gaps to a new equilibrium. Class 2 — single-stock binary catalyst: a clinical readout, regulatory decision or program failure resets the equity’s entire valuation in one session. Class 3 — buyout and strategic capital: an acquisition, merger, tender, divestiture, financing, registration or split event reprices the float against a control value or against the supply of paper. Class 4 — sector rotation: the name moves with its bucket rather than its own news. Class 5 — sell-the-news: a positive disclosure is sold because the outcome was already in the price. Class 6 — stealth accumulation or distribution: the price barely moves while turnover runs multiples of normal.

Thursday’s board was two Class 2 prints, one Class 3, one Class 5, and two names with no clean same-day catalyst at all. Korro Bio is the cleanest Class 2 of the session: a 07:00 ET press release with preclinical data that beat its own prior disclosures, on a stock that had moved +4.6% in the five sessions beforehand. Avalo is Class 2 in its read-across form — not a binary event for Avalo, but a binary event for its only asset’s competitive position, delivered by AbbVie. Moderna is Class 5 in its purest form: data that met its endpoints, sold because the stock had already priced a better version of them. Sunshine Biopharma is Class 3, and specifically the sub-species that recurs in this column whenever a micro-cap loses its bid price: a reverse split announced to restore compliance.

The two names that fit none of the above cleanly are the informative ones. Estrella Immunopharma rose 32.15% on 1.9x volume with no disclosure at all, a week after its October 15 STARLIGHT-1 update, now +73.0% in five sessions. Karyopharm rose 28.68% on 5.3x volume with no disclosure at all, +34.7% in five sessions, into a November 2 earnings date and a fourth-quarter FDA filing-acceptance decision. Neither move had a same-day cause; both had a same-month story. That is what a squeeze looks like when the float is small and the catalyst is dated but not yet arrived.

Top 3 Winners — What Drove Them

KRRO — Korro Bio, +29.71% to $12.05 on 2.26x volume

Korro Bio closed at $12.05, up 29.71% from $9.29, on 476,139 shares — a 2.26x volume ratio against a 210,746-share average, an intraday range of $9.08 to $12.09, and a five-day change of +4.6% going into the print. This is the one mover of the six whose catalyst is same-day, company-issued and unambiguous.

At 07:00 ET on October 22 the company reported preclinical data for KRRO-111, its GalNAc-conjugated RNA-editing candidate for alpha-1 antitrypsin deficiency, an indication where the disease damages both the lung and the liver and where no therapy corrects the underlying genetic defect. In repeat-dose NSG-PiZ mice, editing of SERPINA1 mRNA reached 96%, functional M-AAT accounted for 93% of circulating AAT, and total AAT reached 172 micromolar — roughly six-fold over vehicle at Day 57. In an immunocompetent C57BL/6-PiZ model, whole-liver levels of the pathogenic Z-AAT protein fell 95% versus vehicle at the same timepoint. Single-dose experiments produced up to 91% editing, with M-AAT up to 88% of circulating protein, and both responses remained detectable through at least Day 42 (Yahoo Finance — Korro reports best-in-class preclinical data for KRRO-111, StockTitan — Korro reports best-in-class preclinical data for KRRO-111).

The company guided to a regulatory submission and first-in-human entry in the first half of 2027, and the release was carried as a same-day Form 8-K (MarketScreener — Korro Bio reports preclinical results for KRRO-111, Korro Bio investor relations). The market’s reaction has to be read against the position: $12.05 sits 18% of the way up a $5.20–$42.93 52-week band, the company employs roughly 57 people, and about 11.5% of the float is short. A preclinical dataset moving a stock 30% is normally a statement about a thin float and a short book; here it is also a statement about how little of the AATD opportunity was in the price. Class 2 — single-stock catalyst, cleanly dated and company-issued.

ESLA — Estrella Immunopharma, +32.15% to $0.7268 on 1.92x volume

Estrella Immunopharma closed at $0.7268, up 32.15% from $0.55, on 6.76 million shares — a 1.92x volume ratio against a 3.51 million-share average inflated by its own mid-month spike, roughly $4.9 million of turnover, and a day range of $0.56 to $0.75. No October 22 press release, filing or data announcement was identified. The session opened 17.91% higher in the prior evening’s after-hours tape and simply extended.

The freshest disclosure is a week old. On October 15 the company said the first patient in the STARLIGHT-1 dose-expansion phase had received two EB103 infusions at 5 x 10^6 T cells/kg, three weeks apart, at the recommended Phase 2 dose, and tolerated them through the first month of follow-up, in a CD19/CD22-targeted ARTEMIS T-cell programme (Estrella Immunopharma — first patient treated with two EB103 infusions in STARLIGHT-1 dose expansion, Yahoo Finance — same release). That release produced the first leg of this move; Thursday produced the second and third.

The arithmetic is the analysis. The stock is +73.0% in five sessions, sits at $0.73 inside a $0.24–$3.15 52-week range — 17% of the way up a band it has traversed twice this month — and carries a live structural constraint: a Nasdaq non-compliance notice received in September gives it until March 1, 2027 to restore market value of listed securities above $35 million for ten consecutive sessions. Flagged: no clean same-day catalyst — week-old safety data still being re-rated in a sub-$1 name. Treat the percentage as a statement about liquidity, not about information (MarketWatch — Estrella Immunopharma quote and news, StockTitan — ESLA news feed).

KPTI — Karyopharm Therapeutics, +28.68% to $0.5461 on 5.29x volume

Karyopharm closed at $0.5461, up 28.68% from $0.4244, on 7.47 million shares — a 5.29x volume ratio against a 1.41 million-share average, a day range of $0.42 to $0.55, and a five-day change of +34.7%, the strongest sustained run on the winners’ board. No October 22 release, filing or readout was identified.

What exists is a clock. On August 31 the company submitted a supplemental NDA to the FDA seeking accelerated approval of XPOVIO (selinexor) plus ruxolitinib in JAK inhibitor-naive myelofibrosis, on the strength of the Phase 3 SENTRY trial, and said it expects the agency’s filing-acceptance decision and review timelines in the fourth quarter of 2026 (Karyopharm — supplemental NDA submitted for XPOVIO plus ruxolitinib in myelofibrosis, MarketBeat — KPTI FDA events timeline). Third-quarter results follow on November 2.

That is a real set of catalysts and none of them is Thursday’s. The company has 22.7 million shares out, a $12.4 million market capitalisation, $146.6 million of trailing revenue and a $224.7 million net loss, and the stock sits 2% of the way up a $0.31–$10.99 52-week range — a band set by July’s 69% after-hours collapse (StockAnalysis — Karyopharm statistics, Benzinga — 12 health care stocks moving in Thursday’s intraday session). In that configuration, 5.3x volume and a 29% session is a squeeze in a sub-$1 equity ahead of dated news, not a market discovering something new. Flagged: no clean same-day catalyst — pre-earnings and pre-acceptance positioning.

Top 3 Losers — What Drove Them

AVTX — Avalo Therapeutics, -39.23% to $7.45 on 22.41x volume

Avalo Therapeutics closed at $7.45, down 39.23% from $12.26, on 26.19 million shares — a 22.41x volume ratio, the heaviest relative turnover in the entire dataset, roughly $195 million of notional — after trading between $6.85 and $9.35 and setting a new low beneath the $11.21 floor it had printed on Tuesday.

The cause was another company’s trial. AbbVie reported positive Phase 3 results for lutikizumab, its dual IL-1-alpha/IL-1-beta antibody, in hidradenitis suppurativa — the exact indication where Avalo’s abdakibart (AVTX-009) is the entirety of the equity story (AInvest — Avalo’s 36% rout after AbbVie’s HS data: validation, competition, or overreaction, Tickeron — why Avalo Therapeutics is down 43% today). The read-through is genuinely two-sided, which is what makes the reaction interesting rather than obvious: a validated IL-1 pathway in a disease with no approved systemic therapy is good news for the mechanism and bad news for the moat, and it hands payers and physicians a large-cap alternative in the same class.

The sell side split on which of those dominates. Wedbush cut its price target to $22 from $34 while maintaining an Outperform and arguing that abdakibart’s potential remains intact after the AbbVie data (Benzinga — 12 health care stocks moving in Thursday’s intraday session, MarketBeat — Avalo sets a new 52-week low). The five-day change into the session was +3.5%, so this is one day of competitive re-pricing rather than the resumption of a slide. With a May 2026 offering of 19.73 million shares and 1.4 million pre-funded warrants priced at $17.75 as the reference point for the float, Thursday’s close is 58% below that print, and the company’s roughly $472 million of cash now buys a much larger share of the enterprise than it did on Wednesday morning. Class 2 — competitive read-across, not an Avalo disclosure.

MRNA — Moderna, -17.57% to $202.63 on 2.87x volume

Moderna closed at $202.63, down 17.57% from $245.81, on 49.85 million shares — a 2.87x volume ratio against a 17.37 million-share average, roughly $10.1 billion of turnover, and an intraday range of $180.80 to $241.26 that represented the widest absolute swing on the board. By dollar value it was the largest move in the dataset by an order of magnitude.

The mechanism was a leak, not a result. Partial data from the Phase 3 INTerpath-001 trial of the individualized mRNA cancer vaccine given with Merck’s Keytruda circulated on social media before the companies released it, and the stock fell as much as 25% before the full dataset — which was positive — was published ahead of schedule (CNBC — Moderna stock falls after cancer vaccine data leak, Forbes — Moderna stock plunges 25% after possible cancer vaccine data leak).

The numbers cleared the bar that matters. In more than 1,100 patients, the combination cut the risk of melanoma death or recurrence by 42% and the risk of the cancer spreading by 38%, and Merck closed down about 1.8% — a fraction of Moderna’s decline, which tells you where the expectations sat (Reuters — Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, 24/7 Wall St. — Moderna tumbles 25% after apparent early leak, Motley Fool — Moderna stock plummets 18%). Moderna had run +8.6% in five sessions into the print and is up more than fivefold year-to-date; a 42% risk reduction arrived priced for better than 42%, and an uncontrolled release removed the companies’ ability to frame it. At $202.63, 78% of the way up a $22.28–$254.48 range, Moderna gave back a fifth of its capitalisation in one session on data that met its endpoints. Class 5 — sell-the-news, with a disclosure-control overlay.

SBFM — Sunshine Biopharma, -22.47% to $0.167 on 0.27x volume

Sunshine Biopharma closed at $0.167, down 22.47% from $0.2154, on 3.11 million shares — a 0.27x volume ratio against an 11.65 million-share average, in a $0.15–$0.19 range, on roughly $520,000 of turnover.

The company disclosed the reason before the open: a one-for-twenty reverse stock split effective at market open on October 26, 2026, taking issued and outstanding shares from 15,219,383 to approximately 760,969, undertaken to regain compliance with Nasdaq’s $1.00 minimum bid price requirement (Yahoo Finance / ACCESS Newswire — Sunshine Biopharma announces reverse stock split to maintain Nasdaq listing, StockTitan — Sunshine Biopharma sets 1-for-20 reverse stock split, SquawkNews — Sunshine Biopharma sets 1-for-20 reverse split).

The reaction is the standard one for a compliance split in a sub-$1 name, and the low volume ratio is the tell: this was holders selling into a thin book, not institutions repricing a business. A 1-for-20 split fixes the bid-price arithmetic without changing enterprise value, and it usually signals that the equity has been issuing paper faster than it has been generating value. The stock was already -11.4% over five sessions, now sits below its recorded $0.19 low in a band that tops out at $23.20, and is roughly 99% below that high. Class 3 — capital-structure mechanics, in its reverse-split form.

The Cross-Cutting Pattern

Thursday’s pattern is not a rotation. It is an information-origin pattern, and it is the cleanest example of one this column has recorded.

Look at the six extremes and ask where the price-setting information came from. Avalo fell because of AbbVie’s trial — a competitor’s disclosure, not its own. Moderna fell because of a leaked dataset — a third party’s decision to publish early, on data that were positive. Sunshine Biopharma fell because of a corporate mechanic it announced itself but which contains no information about its business. Estrella rose on a release from a week earlier that the market had already traded through twice. Karyopharm rose on a filing-acceptance decision that has not happened yet. Only Korro Bio was repriced by its own new information, released on schedule, at 07:00 ET, under an 8-K.

That configuration has a specific implication. When the tails of a distribution are set by information arbitrage rather than by clinical results, the individual moves carry less forward information than their magnitudes suggest — a 39% decline driven by a rival’s dataset is a repricing of a competitive position that will take months to resolve, and a 32% advance driven by a one-week-old safety release is a float effect, not a fundamental re-rating. Meanwhile the centre of the distribution — a -0.31% median on 570 names — says the cohort itself is being marked down gently and evenly, twice in a row, while the index falls harder than health care does.

The sector data makes the same point from a different angle. Devices - Surgical led at +1.43% (n=29), Devices - Miscellaneous +0.42% (n=26) and Stem Cells/Cellular Therapy +0.10% (n=23) were the only buckets meaningfully positive, while the three largest clinical buckets were all negative: Small Molecule Pharma -1.04% (n=151), Biologics -1.08% (n=86), Antibodies -0.85% (n=42) — and Diagnostics -2.47% (n=30), Genetics & Genomics -3.41% (n=7) and AI / Machine Learning -4.19% (n=6) were worse. On a day when health care as a sector rose 1.33%, the tools-and-devices end of life sciences outperformed the therapeutics end. That is a defensive bid inside a defensive sector: money buying the picks and shovels and the procedure volume, not the binary outcomes.

The 5 Data Points That Matter

1. Percentage change versus the sector mean. The centre of the distribution was -0.31%. Estrella’s +32.15% is 32.5 points above the median and 32.1 points above its own Stem Cells/Cellular Therapy bucket at +0.10% (n=23) — the widest name-versus-sector gap on the board. Korro’s +29.71% is 30.0 points above the median and 30.3 points above RNA, Peptide & Gene Therapy at -0.61% (n=27), a bucket of 27 names that includes most of the RNA-editing peer group and none of which moved remotely as far. Karyopharm’s +28.68% is 29.0 points above the median and 29.7 points above Small Molecule Pharma at -1.04% (n=151). On the losing side, Avalo’s -39.23% is 38.9 points below the median and 38.2 points below Small Molecule Pharma; Sunshine Biopharma’s -22.47% is 22.2 points below and 21.4 points below; and Moderna’s -17.57% is 17.3 points below the median and 17.5 points below the uncategorised bucket at +0.12% (n=19). The honest read on the sector table is that only the large-sample buckets carry weight — Small Molecule Pharma, Biologics, Antibodies, Diagnostics — and all four were negative.

2. Volume ratio. Participation separated conviction from mechanics with unusual clarity. Avalo printed 22.41x on 26.2 million shares — the single heaviest relative turnover in the dataset, attached to the single worst decline, which is what a genuine competitive re-rating looks like. Lucid Diagnostics printed 20.53x on 43.5 million shares for a -1.71% move — the textbook Class 6 footprint, a name that has fallen -38.6% in five sessions trading 20x normal volume while the price barely moves, i.e. distribution into a flat tape. Profusa printed 11.31x on 44.9 million shares for +20.11%, a bounce inside a -33.7% five-day drawdown. Below them: Aardvark 10.73x for -10.43%, Gain Therapeutics 5.55x for +8.40%, Karyopharm 5.29x, Relmada 5.02x for +2.49%, Arcus 4.47x for +1.31% the session after launching an offering, InspireMD 3.94x for +1.54%, Genelux 3.42x for -4.35%. Two of Thursday’s three biggest winners by percentage — Estrella at 1.92x and Korro at 2.26x — did not crack the top ten by relative volume, which is the cleanest evidence that their moves were about float and short interest rather than about a wave of new buyers.

3. Five-day momentum. Thursday split the extremes along a line that matters: two of the three winners were continuations and two of the three losers were breaking from a flat or positive base. Estrella +73.0% into +32.15% is momentum feeding on itself; Karyopharm +34.7% into +28.68% is the same pattern with a catalyst date attached; Korro +4.6% into +29.71% is the clean case — an event landing on a stock that had not pre-positioned. On the other side, Avalo +3.5% into -39.23% and Moderna +8.6% into -17.57% both fell from positive five-day bases, which means Thursday’s downside was new information, not the continuation of a decline. Sunshine Biopharma -11.4% into -22.47% is the exception: a name already sliding that received a second, mechanical push. A stock that breaks from a rising base on 3x to 22x volume has had something repriced in it; a stock that keeps falling on 0.27x volume has simply lost its bid.

4. Position in range and absolute price. Four of the six trade under $1.25 and five under $8. Karyopharm at $0.5461 sits 2% of the way up a $0.31–$10.99 range — a rounding error from its floor. Estrella at $0.7268 sits 17% up a $0.24–$3.15 range. Sunshine Biopharma at $0.167 is below its recorded $0.19 low in a band that reaches $23.20, having effectively round-tripped a decade of value. On the other side, Korro at $12.05 sits 18% up a $5.20–$42.93 band, Avalo at $7.45 is below the $11.21 low it set two sessions ago in a $11.21–$24.27 band, and Moderna at $202.63 sits 78% up a $22.28–$254.48 range — the only mover of the six whose range position implies a franchise rather than a lottery ticket. That is the structural difference between the two sides of Thursday’s board: the winners were near their floors, and the biggest loser by dollar value was near its ceiling.

5. Cash, dilution and event clocks. On Thursday the balance sheet and the calendar did more work than the science. Avalo has roughly $472 million of cash to fund a Phase 3 in hidradenitis suppurativa, against a $17.75 May offering price that now sits 58% above the market — the company is well funded and its shareholders are deeply underwater. Karyopharm has $146.6 million of trailing revenue, a $224.7 million annual loss and a $12.4 million market capitalisation, which means the sNDA acceptance decision expected this quarter is worth more than the entire equity. Sunshine Biopharma is executing a 1-for-20 split on October 26 to stay listed, having already lost 99% of its 52-week high. Estrella is racing a March 1, 2027 Nasdaq market-value deadline with a $35 million threshold it does not currently meet. Moderna spent Thursday discovering that a leaked dataset can cost $10 billion of turnover in a session regardless of what the data say. And Korro, with 57 employees and a programme entering the clinic in the first half of 2027, is the only name on the board whose next milestone is a scientific one rather than a financial or regulatory one.

What This Synthesis Will and Won’t Tell You

This is a one-day reading and should be read as one. It tells you what moved and why: the 118 anomaly-flagged names, the six data-defined extremes, the signal class behind each, and the cross-cutting pattern — a second consecutive negative session with a shallower median (-0.31%) and wider tails (71.4 points), health care outperforming a falling S&P 500 by 2.50 points while small-cap biotech underperformed it, and a leaderboard on which five of six extremes were driven by information the moving company did not itself release that day. It does not tell you what happens next: whether AbbVie’s HS win turns into a pricing problem for abdakibart or a class-validation tailwind; whether Moderna’s 42% risk reduction is enough to rebuild the multiple the leak destroyed; whether Korro’s preclinical editing numbers survive the translation into humans that the company has scheduled for the first half of 2027; whether Karyopharm’s sNDA is accepted and, if it is, whether a $12.4 million market capitalisation can hold a myelofibrosis launch; whether Estrella reaches its $35 million threshold before March; or what a post-split Sunshine Biopharma looks like at $3.34.

The honest limits are four. First, the catalyst investigation covers the six data-defined top movers only. The rest of the anomaly board carries stories worth naming without investigation: Profusa +20.11% on 11.31x, Elicio +16.17%, Nanobiotix +13.01% with a +21.4% five-day run, CytoSorbents +12.34% after +73.1% in five sessions, OnKure +12.17%, Gain Therapeutics +8.40% on 5.55x, Tenax +7.98% on 3.3 million shares, and on the losing side Biomea Fusion -15.23%, Propanc -13.13%, Heron Therapeutics -12.57%, Senti Biosciences -12.41%, LeonaBio -12.35%, Purple Biotech -11.30%, bioAffinity -11.20%, HeartSciences -10.96%, Aardvark -10.43% on 10.73x. Second, two of the six extremes had no clean same-day catalyst — Estrella entirely, Karyopharm in substance — and they are included because the data placed them there; the flags are the correction, not a substitute for the ranking. Third, sector averages built on small samples are not averages: AI / Machine Learning -4.19% (n=6), Genetics & Genomics -3.41% (n=7) and the regional buckets describe a handful of names each, and the only reads with enough weight behind them are Small Molecule Pharma -1.04% (n=151), Biologics -1.08% (n=86) and Antibodies -0.85% (n=42). Fourth, two consecutive negative medians that are shallower than the two before them cannot be distinguished from a pause. The nine-session sequence — medians of -1.79%, -3.57%, -1.60%, +2.01%, -3.53%, +0.85%, +2.82%, -0.42% and -0.31% — is a violently two-sided tape in which direction is set by the day, not by the week.

What a longer sample would add is the part this format cannot supply: whether a session in which the two largest declines were caused by other companies’ disclosures is a one-off, or the beginning of a phase in which competitive read-across does more price discovery in biotech than company reporting does. Thursday’s answer — a rival’s Phase 3 and a leaked dataset, in the same session, in the same sector — is not evidence of a trend, but it is a reminder that in a sector priced on binary events, the most important disclosure of the day frequently belongs to somebody else.

---

This is editorial analysis, not investment advice. Single-day returns reflect regular-session closing prices on 2026-10-22 and will change with market conditions, clinical readouts, financing terms and regulatory events. Micro-cap and clinical-stage names can experience rapid reversals; several of the names discussed here trade under $5.00, carry pending capital, listing-compliance or going-concern disclosures, or have outstanding offerings, reverse splits and registration statements, and readers should review the underlying filings before drawing conclusions about momentum durability.

Generated 2026-10-22 PT (post-market, after the 4 PM ET close). Market data compiled from public quote and historical market-data feeds; sector categorisation from public company filings and listings; company backgrounds compiled from public investor disclosures and press releases. For the prior synthesis, see Daily Biotech Movers — 2026-10-21.

Sources: [Korro Bio — best-in-class preclinical data for KRRO-111 in alpha-1 antitrypsin deficiency, 2026-10-22]; [Estrella Immunopharma — first patient treated with two EB103 infusions in STARLIGHT-1 dose-expansion phase, 2026-10-15]; [Karyopharm Therapeutics — supplemental NDA submitted for XPOVIO plus ruxolitinib in myelofibrosis, 2026-08-31]; [AbbVie — positive Phase 3 results for lutikizumab in hidradenitis suppurativa, 2026-10-22, as reported by AInvest]; [Sunshine Biopharma — one-for-twenty reverse stock split effective 2026-10-26, 2026-10-22]; [Merck and Moderna — Phase 3 INTerpath-001 results in resected melanoma, 2026-10-22, as reported by Reuters, CNBC, Forbes and STAT]; public quote and historical market-data feeds; company investor-relations disclosures.